CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE

Go back to CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE

CVS Health (CVS) PT Lowered to $77 at BofA Securities

May 2, 2024 5:38 AM EDT

BofA Securities analyst Michael Cherny lowered the price target on CVS Health (NYSE: CVS) to $77.00 (from $95.00) while maintaining a Buy rating.

The analyst comments "Shares of CVS currently trade at 8x earnings, implying investors have substantial doubt the company can... More

CVS Health (CVS) stock tumbles as earnings, guidance miss expectations

May 1, 2024 6:55 AM EDT

(Updated - May 1, 2024 11:42 AM EDT)

CVS Health (NYSE: CVS) reported a decline in first-quarter profits and slashed its full-year earnings outlook, sending shares down more than 17% Wednesday as both earnings and revenue fell short of Wall Street expectations. The healthcare giant posted adjusted earnings per share (EPS) of $1.33 for the quarter, which was significantly below the analyst consensus of $1.71. Revenue for the quarter was $88.4 billion, also missing the consensus estimate of $89.33 billion.

The company's first-quarter revenue saw a 3.7% increase compared to the same period last year, driven by growth in the Health Care... More

CVS Health (CVS) Misses Q1 EPS by 38c; Lowers Outlook

May 1, 2024 6:34 AM EDT

CVS Health (NYSE: CVS) reported Q1 EPS of $1.33, $0.38 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $88.4 billion versus the consensus estimate of $89.33 billion.

GUIDANCE:

CVS Health sees FY2024 EPS of $7.00, versus the consensus of... More